Source Post

Novo Nordisk ($NVO) Struggles | PayPal ($PYPL) Takeover

The RoseMar 15, 2026

The creator discusses Novo Nordisk's recent struggles due to trial results showing their drug is less effective than Eli Lilly's, leading to a significant stock drop. They also explore the potential for Novo Nordisk to adjust drug dosages and pricing to remain competitive. The creator then shifts to PayPal, highlighting rumors of a potential takeover by Stripe and analyzing PayPal's financial health and market position. Finally, they discuss their own portfolio's performance, mentioning several stocks in the red, including Novo Nordisk, and their strategy for managing these positions.

Linked Mentions

Tickers discussed in this post

RDDTNeutralLow ConvictionResearch Only

Reddit is mentioned as a red position within the creator's portfolio.

OSCRNeutralLow ConvictionResearch Only

Oscar Health is mentioned as a position in the creator's portfolio that is currently in the red.

SOFIBullishMedium ConvictionSignal-backedSecondary

SoFi is highlighted as having good short-term potential, with the possibility of a 50% increase in the next six months, and is considered a potential investment.

DUOLBullishMedium ConvictionSignal-backedSecondary

Duolingo is viewed as having significant upside potential, possibly doubling or tripling, and is considered for reinvestment from Novo Nordisk.

TEMBullishMedium ConvictionSignal-backedSecondary

Tempus AI is seen as having high short-term potential due to strong revenue growth and is considered a candidate for reinvestment from Novo Nordisk.

ADBENeutralLow ConvictionResearch Only

Adobe is noted as a red position in the creator's portfolio and is considered a potential software play for reinvestment.

UNHNeutralLow ConvictionResearch Only

UnitedHealth Group is mentioned as one of the positions in the creator's portfolio that is currently in the red.

PYPLBullishMedium ConvictionSignal-backedPrimary

PayPal is considered a prime acquisition target due to its strong free cash flow and market position, with Stripe being a potential buyer.

LLYNeutralLow ConvictionSignal-backedSecondary

Eli Lilly's drug Zepbound is noted as superior in weight loss trials, and they may be forced to drop prices in response to Novo Nordisk's potential cuts.

NVOBearishMedium ConvictionSignal-backedPrimary

The creator is considering reducing their Novo Nordisk position due to concerns about price cuts, competition, and potential short-term struggles, suggesting it may trade sideways in 2026.

Linked Signals

Tracked calls opened from this post

No linked signals were opened directly from this post.